Page 342 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

320 PART III Therapeutic Modalities for the Cancer Patient

37. Esin E, Yalcin S: Neuropathic cancer pain: what we are dealing 57. Gruen ME, Griffith EH, Thomson AE, et al.: Criterion validation
with? how to manage it? Onco Targets Ther 7:599–618, 2014. testing of clinical metrology instruments for measuring degenera-
38. Hamilton TA, Cook JJ, Braund KG, Morrison WB MJ: Vincris- tive joint disease associated mobility impairment in cats, PLoS One
VetBooks.ir tine-induced peripheral neuropathy in a dog, J Am Vet Med Assoc 58. Giuffrida MA, Brown DC, Ellenberg SSFJ: Development and psy-
10:1–22, 2015.
198:635–638, 1991.
39. Martins B de C, Martins G de C, Horta R dos S, et al.: Sensory-
tionnaire, an instrument designed to measure quality of life in dogs
motor neuropathy due to vincristine treatment in a dog, Acta Sci chometric testing of the canine owner-reported quality of life ques-
Vet 42:1–4, 2014. with cancer, J Am Vet Med Assoc 252:1073–1083, 2018.
40. Lynch S, Savary-Bataille K, Leeuw B, et al.: Development of a ques- 59. Mellanby RJ, ME H, JM D: Owners’ assessments of their dog’s
tionnaire assessing health-related quality-of-life in dogs and cats quality of life during palliative chemotherapy for lymphoma,
with cancer, Vet Comp Oncol 9:172–182, 2011. J Small Anim Pract 44:100–103, 2003.
41. Hamilton MJ, Sarcornrattana O, Illiopoulou M, et al.: Ques- 60. Yazbek KVB, Fantoni DT: Validity of a health-related quality-of-
tionnaire-based assessment of owner concerns and doctor respon- life scale for dogs with signs of pain secondary to cancer, J Am Vet
siveness: 107 canine chemotherapy patients, J Small Anim Pract Med Assoc 226:1354–1358, 2005.
53:627–633, 2012. 61. Tzannes S, Hammond MF, Murphy S, et al.: Owners “perception
42. Giuffrida MA, Farrar JT, Brown DC: Psychometric proper- of their cats” quality of life during COP chemotherapy for lym-
ties of the Canine Symptom Assessment Scale, a multidimen- phoma, J Feline Med Surg 10:73–81, 2008.
sional owner-reported questionnaire instrument for assessment 62. Brown DC, Boston R, Coyne JC, et al.: A novel approach to the
of physical symptoms in dogs with solid tumors, J Vet Intern Med use of animals in studies of pain: validation of the canine brief pain
251(12):1405–1414, 2014. inventory in canine bone cancer, Pain Med 10:133–142, 2009.
43. Fleming JM, Creevy KE, Promislow DEL: Mortality in North 63. Crawford AH, Tivers MS, Adamantos SE: Owner assessment of
American dogs from 1984 to 2004: an investigation into age-, size-, dogs’ quality of life following treatment of neoplastic haemoperito-
and breed-related causes of death, J Vet Intern Med 25:187–198, neum, Vet Rec 170:566, 2012.
2011. 64. Iliopoulou MA, Kitchell BE, Yuzbasiyan-Gurkan V: Development
44. Greco MT, Roberto A, Corli O, et al.: Quality of cancer pain man- of a survey instrument to assess health-related quality of life in
agement: an update of a systematic review of undertreatment of small animal cancer patients treated with chemotherapy, J Am Vet
patients with cancer, J Clin Oncol 32:4149–4154, 2014. Med Assoc 242:1679–1687, 2013.
45. Biller B, Berg J, Garrett L, et al.: AAHA Oncology guidelines for 65. Mullan S: Assessment of quality of life in veterinary practice: devel-
dogs and cats, J Am Anim Hosp Assoc 52:181–204, 2016. oping tools for companion animal carers and veterinarians, Vet Med
46. Arpinelli F, Bamfi F: The FDA guidance for industry on PROs: Res Reports 6:203–210, 2015.
the point of view of a pharmceutical company, Health Qual Life 66. Hansen BD, Lascelles BDX, Keene BW, et al.: Evaluation of an
Outcomes 4(1–5), 2006. accelerometer for at-home monitoring of spontaneous activity in
47. Apolone G, De CG, Brunetti M, et al.: Health-related quality of life dogs, Am J Vet Res 68:468–475, 2007.
(HR-QOL) and regulatory issues. An assessment of the European 67. Lascelles BDX, Hansen BD, Roe S, et al.: Evaluation of client-
Agency for the Evaluation of Medicinal Products (EMEA) recom- specific outcome measures and activity monitoring to measure
mendations on the use of HR-QOL measures in drug approval, pain relief in cats with osteoarthritis, J Vet Intern Med 21:410–416,
Pharmacoeconomics 19:187–195, 2001. 2007.
48. Muller C, Gaines B, Gruen M, et al.: Evaluation of clinical metrol- 68. Brown DC, Boston RC, Farrar JT: Use of an activity monitor to
ogy instrument in dogs with osteoarthritis, J Vet Intern Med detect response to treatment in dogs with osteoarthritis, J Am Vet
30:836–846, 2016. Med Assoc 237:66–70, 2010.
49. Hercock CA, Pinchbeck G, Giejda A, et al.: Validation of a client- 69. Wernham BGJ, Trumpatori B, Hash J, et al.: Dose reduction of
based clinical metrology instrument for the evaluation of canine meloxicam in dogs with osteoarthritis-associated pain and impaired
elbow osteoarthritis, J Small Anim Pract 50:266–271, 2009. mobility, J Vet Intern Med 25:1298–1305, 2011.
50. Walton MB, Cowderoy E, Lascelles D, et al.: Evaluation of con- 70. Lascelles BD, Knazovicky D, Case B, et al.: A canine-specific anti-
struct and criterion validity for the “Liverpool osteoarthritis in nerve growth factor antibody alleviates pain and improves mobil-
dogs” (LOAD) clinical metrology instrument and comparison to ity and function in dogs with degenerative joint disease-associated
two other instruments, PLoS One 8, 2013 pain, BMC Vet Res 11:1–12, 2015.
51. Brown DC, Boston RC, Coyne JC, et al.: Development and psy- 71. Corbee RJ, Barnier MMC, van de Lest CHA, et al.: The effect of
chometric testing of an instrument designed to measure chronic dietary long-chain omega-3 fatty acid supplementation on owner’s
pain in dogs with osteoarthritis, 68:631–637, 2007. perception of behaviour and locomotion in cats with naturally
52. Brown C: Ability of the canine brief pain inventory to detect occurring osteoarthritis, J Anim Physiol Anim Nutr (Berl) 97:846–
response to treatment in dogs with osteoarthritis, J Am Vet Med 853, 2013.
Assoc 233:1278–1283, 2008. 72. Lascelles BDX, Court MH, Hardie EM, et al.: Nonsteroidal anti-
53. Hielm-Björkman AK, Rita HTR: Psychometric testing of the inflammatory drugs in cats: a review, Vet Anaesth Analg 34:228–
Helsinki chronic pain index by completion of a questionnaire in 250, 2007.
Finnish by owners of dogs with chronic signs of pain caused by 73. Gruen ME, Thomson AE, Griffith EH, et al.: A feline-specific anti-
osteoarthritis, Am J Vet Res 70:727–734, 2009. nerve growth factor antibody improves mobility in cats with degen-
54. Benito J, DePuy V, Hardie E, et al.: Reliability and discrimi- erative joint disease-associated pain: a pilot proof of concept study,
natory testing of a client-based metrology instrument, feline J Vet Intern Med 30:1138–1148, 2016.
musculoskeletal pain index (FMPI) for the evaluation of degen- 74. Brown DC, Michel KE, Love M, et al.: Evaluation of the effect
erative joint disease-associated pain in cats, Vet J 196:368–373, of signalment and body conformation on activity monitoring in
2013. companion dogs, Am J Vet Res 71:322–325, 2010.
55. Benito J, Hansen B, Depuy V, et al.: Feline musculoskeletal pain 75. Wolvers MDJ, Bussmann JBJ, Bruggeman-Everts FZ, et al.: Physi-
index: responsiveness and testing of criterion validity, J Vet Intern cal behavior profiles in chronic cancer-related fatigue, Int J Behav
Med 27:474–482, 2013. Med 25:30–37, 2018.
56. Gruen ME, Griffith E, Thomson A, et al.: Detection of clinically 76. Briley JD, Williams MD, Freire M, et al.: Feasibility and repeatabil-
relevant pain relief in cats with degenerative joint disease associated ity of cold and mechanical quantitative sensory testing in normal
pain, J Vet Intern Med 28:346–350, 2014. dogs, Vet J 199:245–250, 2014.